ABSTRACT

Human papilloma viruses (HPVs) have been acknowledged to be the leading risk factor of cervical intraepithelial lesion creation (CIN) and cervical cancer development (CxCa). Many different techniques have been created and utilized in HPV detection and monitoring with a vast amount of them being commercialized and few of them integrated in official screening strategies. A growing trend for DNA typing of the 14 most commonly accepted high risk HPV types has been introduced, supporting that in many cases molecular testing could replace classic morphologic diagnostic routines, even though DNA detection has lower specificity than other molecular and morphology tests. However, there have been limited attempts in combining data from all different techniques to provide efficient patient triaging schemes, since, apart from the obvious increase of patient cost, the amount of data and its interpretation in patient management has been impossible. Complex computer based clinical support decision systems, many of which are based on artificial intelligence may abolish these limitations.

DOI: 10.4018/978-1-4666-8828-5.ch005
**INTRODUCTION**

Human papilloma viruses (HPV) are members of the papillomaviridae family. HPVs are small (7,000-8,500bp) double stranded DNA viruses with no RNA phase in their life cycle that can only be reproduced in keratinocytes. Over 100 different types have been identified and isolated, both in humans and animals (de Villiers, Fauquet, Broker et al, 2004). Around 40 types have been isolated from human cervical specimens and HPVs have been classified, according to their epidemiology in cervical lesions, as low risk and high risk (Dunne, Unger, Sternberg et al, 2007; Munoz, Bosch, Sanjose et al, 2003; Trottier & Franco, 2006). Although HPVs have been mostly isolated from cervical samples they have also been detected in samples from the anus, vulva, vagina, skin and even head and neck cancers.

HPVs are small double-stranded DNA viruses encoding ten proteins in total, out of which two (E6 and E7) are considered oncoproteins (Münger, Basile, Duensing et al, 2001; Mantovani & Banks, 2001) and two (L1 and L2) are the structural proteins of the viral capsid. The rest proteins include one helicase (E1), one transcription factor (E2), two proteins that induce host proliferation (E5) and viral replication (E4) and a short protein that is expressed only in few papillomavirus types that may substitute for the E6 open reading frame. E6 has been shown to interact with the p53 tumor suppressor protein leading to its degradation, while E7 inactivates members of the pRB family of tumor suppressor proteins and activates telomeres. Both proteins enhance cell proliferation and down regulate apoptosis.

HPVs proteins are named after the stage of the viral infection cycle; E proteins are early expressed proteins and are responsible for the replication of the virus, while L proteins are late expressed proteins after the virus has replicated. HPVs infect cells of the basal epithelium of the cervix via minor abrasions of the squamous epithelium. At first the virus reproduces as an extra-chromosomal plasmid during cell division and these infections are sub-clinical. Later on and after the expression of viral oncogenes, the virus reproduces by thousands and infection spreads in more cells (activated infection). After a long lasting infection, the virus is proposed to be integrated in the host genome leading to deregulation of gene expression, disruption of tumor suppressor genes and the accumulation of genetic changes that ultimately result in malignant transformation of epithelial cells (Andersson, Safari, Mints et al, 2005). A persistent infection by HPV aided by other parameters results in HPV integration in host DNA leading to progression to high grade lesions (Wallin, Wiklund, Angström et al, 1999). Most HPV infections are cleared by the host’s immune system before they progress to the creation of intra-epithelial lesions. Only persistent infection with high risk HPV types has been acknowledged as the most important risk factor for cervical cancer development (Walboomers, Jacobs, Manos et al, 1999).

First connection of HPVs with cancer was proposed by Stefania Jablonska in Poland in 1972 in epidermodysplasia verruciformis (Jabłońska, Orth, Jarzabek-Chorzelska et al, 1978). Initial evidence supporting that theory emerged in 1978, when Jablonska and Gerard Orth discovered HPV-5 in skin cancer. In 1976 Harald zur Hausen published the hypothesis that human papillomavirus plays an important role in the cause of cervical cancer, and finally in 1983 and 1984 zur Hausen and his collaborators identified HPV16 and HPV18 in cervical cancer (zur Hausen, 1976). HPVs’ linking to cervical carcinogenesis has led to the award of the 2008 Nobel Prize of medicine to Dr. Herald zur Hausen for his pioneering work (zur Hausen, 1976, 1991).

HPV infection prevalence can vary substantially across different age groups, study populations and countries (Revzina & Diclemente, 2005). Although the prevalence of HPV is about the same worldwide and Cervical Intraepithelial Neoplasias (CIN) develop gradually resulting in
Related Content

The Economics of Long-Term Care: Key Concepts and Major Financing and Delivery Models
Peter P. Yuen (2018). *Sustainable Health and Long-Term Care Solutions for an Aging Population (pp. 1-18).*
[www.igi-global.com/chapter/the-economics-of-long-term-care/185685?camid=4v1a](www.igi-global.com/chapter/the-economics-of-long-term-care/185685?camid=4v1a)

Healthcare Computer Reasoning Addressing Chronically Ill Societies Using IoT: Deep Learning AI to the Rescue of Home-Based Healthcare
David Mendes, Manuel José Lopes, Artur Romão and Irene Pimenta Rodrigues (2019). *Chronic Illness and Long-Term Care: Breakthroughs in Research and Practice (pp. 720-736).*
[www.igi-global.com/chapter/healthcare-computer-reasoning-addressing-chronically-ill-societies-using-iot/213378?camid=4v1a](www.igi-global.com/chapter/healthcare-computer-reasoning-addressing-chronically-ill-societies-using-iot/213378?camid=4v1a)

QSAR of Antioxidants
Omar Deeb and Mohammad Goodarzi (2017). *Oncology: Breakthroughs in Research and Practice (pp. 408-433).*
[www.igi-global.com/chapter/qsar-of-antioxidants/158929?camid=4v1a](www.igi-global.com/chapter/qsar-of-antioxidants/158929?camid=4v1a)

Empowering Cochlear Implant Users in Their Home Environment by eHealth Solutions
Filiep Vanpoucke, Birgit Philips, Cas Smits, Paul J. Govaerts, Inge Doorn and Thomas Stainsby (2019). *Tele-Audiology and the Optimization of Hearing Healthcare Delivery (pp. 86-120).*
[www.igi-global.com/chapter/empowering-cochlear-implant-users-in-their-home-environment-by-ehealth-solutions/220313?camid=4v1a](www.igi-global.com/chapter/empowering-cochlear-implant-users-in-their-home-environment-by-ehealth-solutions/220313?camid=4v1a)